Edwards Lifesciences Corporation (EW) Cash Flow Statement

The extreme quarterly volatility in OCF/NI, ranging from -0.33 to 4.94, appears driven by working capital timing, particularly inventory at customer locations and receivables, rather than fundamental earnings quality. Excluding the outlier quarters, the median conversion ratio hovers near 1.0, suggesting that reported earnings are generally backed by cash. Investors should monitor the consistency of this ratio as the Critical Care divestiture proceeds, as it may alter the working capital profile.

The negative FCF in 2024Q4 and 2026Q1 was primarily due to large working capital outflows, notably -$463.1M and -$501.5M respectively, which appear to be timing-related rather than operational deterioration. The subsequent quarters show strong FCF generation, with 2026Q2 FCF margin of 33.6% exceeding the peer average, indicating robust cash generation from core operations. However, the volatility suggests that quarterly FCF should be assessed on a trailing twelve-month basis to smooth out working capital noise.

EW's capital intensity is significantly lower than typical medtech peers, reflecting its asset-light manufacturing and reliance on outsourced components. The consistent CapEx/Revenue ratio around 3-6% suggests that most spending is maintenance-oriented, with limited growth capex required to support the TAVR and TMTT expansion. This low capital requirement supports high FCF conversion and provides flexibility for capital returns or strategic investments.

The large positive working capital changes in 2024Q3 and 2025Q4 suggest that EW is building inventory at customer locations, which may be a leading indicator of future revenue as valves are implanted. Conversely, the negative swings in 2024Q4 and 2026Q1 indicate destocking or timing of collections, which can distort quarterly cash flow. Investors should monitor the net working capital trend over multiple quarters to assess whether revenue growth is being supported by inventory build-up rather than end-demand.

The absence of dividends and inconsistent buyback activity suggests that management is prioritizing internal reinvestment and strategic flexibility, particularly given the pending $4.2B Critical Care divestiture. The large buyback in 2026Q1 may indicate opportunistic repurchasing, but the overall capital deployment appears conservative. Following the divestiture, investors should watch for a potential increase in capital returns or M&A activity in the TMTT space.

The cumulative OCF/NI ratio of approximately 0.68 over the period is skewed by the $3.1B net income in 2024Q3, which likely included one-time gains. Excluding that quarter, the ratio approaches 1.0, suggesting that core earnings are largely cash-converted. The gap between net income and operating cash flow appears driven by non-cash items like D&A and SBC, as well as working capital timing, rather than aggressive revenue recognition. This supports the quality of EW's earnings.